• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Overview Of Value Stocks In The Healthcare Sector

    1/15/24 9:42:57 AM ET
    $AGRX
    $PBLA
    $PROC
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email

    What is a Value Stock?

    A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

    Below is a list of notable value stocks in the healthcare sector:

    1. Agile Therapeutics (NASDAQ:AGRX) - P/E: 0.25
    2. Panbela Therapeutics (NASDAQ:PBLA) - P/E: 0.0
    3. Procaps Gr (NASDAQ:PROC) - P/E: 8.96
    4. Exicure (NASDAQ:XCUR) - P/E: 0.43
    5. Zymeworks (NASDAQ:ZYME) - P/E: 3.4

    Agile Therapeutics's earnings per share for Q3 sits at $-1.47, whereas in Q2, they were at -3.1. Most recently, Panbela Therapeutics reported earnings per share at $-2.42, whereas in Q2 earnings per share sat at $-7.95. Procaps Gr has reported Q3 earnings per share at $0.08, which has decreased by 70.37% compared to Q2, which was 0.27. Exicure has reported Q2 earnings per share at $-0.68, which has increased by 2.86% compared to Q1, which was -0.7. This quarter, Zymeworks experienced an increase in earnings per share, which was $-0.75 in Q2 and is now $-0.38.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $PBLA
    $PROC
    $XCUR

    CompanyDatePrice TargetRatingAnalyst
    Zymeworks Inc.
    $ZYME
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    Zymeworks Inc.
    $ZYME
    10/24/2025$15.00Equal Weight
    Wells Fargo
    Zymeworks Inc.
    $ZYME
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    Zymeworks Inc.
    $ZYME
    10/10/2025$30.00Buy
    B. Riley Securities
    Zymeworks Inc.
    $ZYME
    5/20/2025Buy
    TD Cowen
    Zymeworks Inc.
    $ZYME
    12/16/2024$18.00Neutral → Overweight
    Analyst
    Zymeworks Inc.
    $ZYME
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

    VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company's partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera® (zanidatamab-hrii) at the American Association for Cancer Research (AACR) Annual Meeting, being held April 17-22, 2026 in San Diego, CA. "We are pleased to see the continued clinical progress of zanidatamab reflected in multiple presentations at AACR," said Ken Galbraith, Chair, Chief Executive Off

    3/18/26 7:46:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

    New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC)New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platform VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts

    3/17/26 5:02:34 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

    Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zymeworks Inc. (NASDAQ:ZYME) today announced an agre

    3/2/26 6:10:00 AM ET
    $RPRX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Mekan Sabeen claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    2/2/26 8:37:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Exicure Hitron Inc. sold $1,162,652 worth of shares (258,367 units at $4.50), decreasing direct ownership by 14% to 1,598,947 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    1/21/26 12:46:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    SEC Filings

    View All

    SEC Form 144 filed by Zymeworks Inc.

    144 - Zymeworks Inc. (0001937653) (Subject)

    3/6/26 9:00:02 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Zymeworks Inc.

    S-8 - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 7:23:59 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 6:28:54 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

    VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also

    10/9/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

    VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors. "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continu

    8/11/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PBLA
    $PROC
    $XCUR
    Financials

    Live finance-specific insights

    View All

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

    VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET). About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a

    2/12/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

    Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J)Eligible to receive up to $440.0 million in potential near-term milestone payments upon successful global regulatory approvals of Ziihera® in GEA Successful commercialization of Ziihera and execution of partnership strategy are expected to drive substantial royalty and milestone revenues with carefully managed R&D

    11/18/25 1:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care